Latest News

Alcon increases bid for Staar Medical Technology to $1.6 billion

Alcon, a Swiss eyecare company, has 'increased its offer to purchase 'Staar Surgical to $30.75 in cash per share, the company announced on Tuesday. The medical technology firm is now valued at $1.6 billion.

Alcon's initial offer, which was agreed on in early August, valued Staar at $1.5 billion. The bid was met with strong opposition from Staar shareholders.

Alcon said that it has also reduced the level of payments made to Staar executives if the deal goes through. Staar's shareholders were urged to vote in favor of the deal at a meeting held on December 19, according to a statement.

Voting had been completed.

Three times the meeting was postponed. Broadwood Partners, Staar’s largest investor, who opposed the initial proposal, announced plans in October to call a shareholders?meeting for removal of several directors.

Alcon stated that "this best and final offer is a clear choice for the stockholders of 'Staar: a substantial, certain?premium or an uncertain future linked to a dissident?activist with a dubious track record."

Alcon stated that Staar board approved the higher bid and that it is expected for the transaction to close by early 2026.

Staar Surgical shares rose 10.4% in premarket trading to $25.6. (Reporting and editing by Matt Scuffham; Maria Rugamer)

(source: Reuters)